Therefore, we think high BCL-2 levels in residual CLL cells after CDK9 inhibitor therapy represent a rationale for combining CDK9 inhibitor treatment with a BCL-2 inhibitor such as venetoclax to achieve deeper CLL remissions or potentially cure. The gene discussed is CDK9; the disease is B-cell chronic lymphocytic leukemia.